Second allogeneic haematopoietic stem cell transplantation for non-malignant diseases.
We retrospectively analysed clinical outcomes of 152 patients with non-malignant diseases (NMDs) who underwent a second allogeneic haematopoietic stem cell transplantation (HSCT), using a composite end-point, graft-versus-host disease (GVHD)-free, relapse (i.e. graft failure)-free and subsequent transplant-free surviva...